Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company that entered the public markets through a business combination with OTR Acquisition Corp., a blank-check company sponsored by OTR Acquisition Holdings LLC that completed its initial public offering in 2021. The combined company is focused on oncology therapeutics, including antibody-drug conjugate programs. On November 7, 2024, Peak Bio filed an 8-K current report with the Securities and Exchange Commission disclosing a material corporate event. The company continues to operate as a publicly listed entity on Nasdaq following the de-SPAC transaction. For full filing history, sponsor data, and real-time analytics on PKBO and the broader SPAC universe, sign up for SpacDesk.